Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis
Kirkpatrick, W.R.; Coco, B.J.; Patterson, T.F.
Antimicrobial Agents and ChemoTherapy 50(4): 1567-1569
2006
ISSN/ISBN: 0066-4804
PMID: 16569887
DOI: 10.1128/aac.50.4.1567-1569.2006
Accession: 012547606
We evaluated combinations of voriconazole (VRC) and liposomal amphotericin B (L-AMB) in a guinea pig invasive aspergillosis model. Simultaneous VRC and L-AMB was most effective, although VRC monotherapy was also effective. These regimens as well as sequential L-AMB followed by VRC were more effective than L-AMB alone or VRC followed by L-AMB.
PDF emailed within 0-6 h: $19.90
Related References
Chandrasekar, P.H.; Cutright, J.L.; Ganesan, L.; Manavathu, E.K. 2002: Antifungal activity of voriconazole alone and in two-drug combination with amphotericin B in a guinea pig pulmonary aspergillosis model International Journal of Infectious Diseases 6(Suppl 2): 2S51Hamada, N.; Ishiga, M.; Tanaka, S.; Ooue, Y.; Itano, J.; Tanaka, H.; Yuzurio, S.; Horiuchi, T.; Suwaki, T.; Kimura, G.; Tanimoto, Y. 2021: Successful Treatment of Antifungal Combination Therapy with Inhaled Liposomal Amphotericin B and Oral Voriconazole for Intractable Chronic Progressive Pulmonary Aspergillosis Internal Medicine 60(15): 2465-2468
Takazono, T.; Izumikawa, K.; Mihara, T.; Kosai, K.; Saijo, T.; Imamura, Y.; Miyazaki, T.; Seki, M.; Kakeya, H.; Yamamoto, Y.; Yanagihara, K.; Kohno, S. 2009: Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis Antimicrobial Agents and ChemoTherapy 53(8): 3508-3510
Grau, S.; Azanza, J.R.; Ruiz, I.; Vallejo, C.; Mensa, J.; Maertens, J.; Heinz, W.J.; Barrueta, J.A.; Peral, C.; Mesa, F.J.ús.; Barrado, M.; Charbonneau, C.; Rubio-Rodríguez, D.ío.; Rubio-Terrés, C. 2017: Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain Clinicoeconomics and Outcomes Research: Ceor 9: 39-47
Graybill, J.R.; Bocanegra, R.; Gonzalez, G.M.; Najvar, L.K. 2003: Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin Journal of Antimicrobial ChemoTherapy 52(4): 656-662
Chandrasekar, P.H.; Cutright, J.L.; Manavathu, E.K. 2004: Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 10(10): 925-928
Patterson, T.F.; Boucher, H.W.; Herbrecht, R.; Denning, D.W.; Lortholary, O.; Ribaud, P.; Rubin, R.H.; Wingard, J.R.; DePauw, B.; Schlamm, H.T.; Troke, P.; Bennett, J.E. 2005: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 41(10): 1448-1452
Ostermann, H.; Solano, C.; Jarque, I.; Garcia-Vidal, C.; Gao, X.; Barrueta, J.A.; De Salas-Cansado, M.; Stephens, J.; Xue, M.; Weber, B.; Charbonneau, C. 2014: Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain Bmc Pharmacology and Toxicology 15: 52
Elanjikal, Z.; Sörensen, J.; Schmidt, H.; Dupuis, W.; Tintelnot, K.; Jautzke, G.ün.; Klingebiel, T.; Lehrnbecher, T. 2003: Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis Pediatric Infectious Disease Journal 22(7): 653-656
Xue, M.; Gao, X.; Ferreira, C.N.; Stephens, J.M.; Haider, S.; Figueiredo Valente, M.L.; Charbonneau, C. 2015: Cost Analysis of Voriconazole Versus Liposomal Amphotericin B for Primary Therapy of Invasive Aspergillosis among High-Risk Hematologic Cancer Patients in Brazil Value in Health 18(7): A820
Helou, G; Gao, C; Xue, M; Tarcha, N; Charbonneau, C 2016: Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin For Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Lebanon Value in Health 19(7): A583-A584
Clemons, K.V.; Espiritu, M.; Parmar, R.; Stevens, D.A. 2005: Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis Antimicrobial Agents and ChemoTherapy 49(12): 4867-4875
Thaqafi, A.A.; Xue, M.; Farahat, F.; Gao, X.; Wafy, M.H.; Fahti, M.; Ibrahim, A.; Charbonneau, C. 2015: Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia Value in Health 18(7): A667
Pagano, L.; Valentini, C.G.; Fianchi, L.; Caira, M. 2011: Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? Journal of ChemoTherapy 23(1): 5-8
Yilmaz, D.; Balkan, C.; Ay, Y.; Akin, M.; Karapinar, B.; Kavakli, K. 2011: A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections Mycoses 54(3): 234-242